Margaret E. Macy

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren et al. · The Lancet Oncology · 2019 · 343 citations

Medicine, Oncology, Pharmacotherapy +17

Mobilization of hobo elements residing within the decapentaplegic gene complex: Suggestion of a new hybrid dysgenesis system in Drosophila melanogaster

Ronald K. Blackman, R Grimaila, Margaret E. Macy et al. · Cell · 1987 · 190 citations

Life Sciences, Genetics, Molecular Genetics +4

Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)

Ami V. Desai, Giles Robinson, Karen Gauvain et al. · Neuro-Oncology · 2022 · 138 citations · Full text

Medicine, Oncology, Pharmacology +17

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

Kelly C. Goldsmith, Julie R. Park, Kimberly Kayser et al. · Nature Medicine · 2023 · 125 citations · Full text

Medicine, Oncology, Pharmacology +10

CFEOM3: a new extraocular congenital fibrosis syndrome that maps to 16q24.2-q24.3.

E J Doherty, Margaret E. Macy, S.M. Wang et al. · PubMed · 1999 · 104 citations

Life Sciences, Genetics, Ophthalmology +15